Ende Zhao
Overview
Explore the profile of Ende Zhao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
3111
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Encarnacion-Rosado J, Sohn A, Biancur D, Lin E, Osorio-Vasquez V, Rodrick T, et al.
Nat Cancer
. 2023 Oct;
5(1):85-99.
PMID: 37814010
Pancreatic ductal adenocarcinoma (PDAC) cells use glutamine (Gln) to support proliferation and redox balance. Early attempts to inhibit Gln metabolism using glutaminase inhibitors resulted in rapid metabolic reprogramming and therapeutic...
2.
Werba G, Weissinger D, Kawaler E, Zhao E, Kalfakakou D, Dhara S, et al.
Nat Commun
. 2023 Jul;
14(1):3912.
PMID: 37400453
No abstract available.
3.
Wan S, Zhao E, Freeman D, Weissinger D, Krantz B, Werba G, et al.
Front Immunol
. 2023 Apr;
14:1177713.
PMID: 37033968
[This corrects the article DOI: 10.3389/fimmu.2023.1067352.].
4.
Oh G, Wang A, Wang L, Li J, Werba G, Weissinger D, et al.
J Clin Invest
. 2023 Mar;
133(11).
PMID: 36976649
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy that harbors mutations in homologous recombination-repair (HR-repair) proteins in 20%-25% of cases. Defects in HR impart a specific vulnerability to poly...
5.
Wan S, Zhao E, Weissinger D, Krantz B, Werba G, Freeman D, et al.
Front Immunol
. 2023 Feb;
14:1067352.
PMID: 36798126
Hepato-pancreatico-biliary (HPB) malignancies are difficult-to-treat and continue to to have a high mortality and significant therapeutic resistance to standard therapies. Immune oncology (IO) therapies have demonstrated efficacy in several solid...
6.
Werba G, Weissinger D, Kawaler E, Zhao E, Kalfakakou D, Dhara S, et al.
Nat Commun
. 2023 Feb;
14(1):797.
PMID: 36781852
The tumor microenvironment (TME) in pancreatic ductal adenocarcinoma (PDAC) is a complex ecosystem that drives tumor progression; however, in-depth single cell characterization of the PDAC TME and its role in...
7.
Hu J, Huang H, Xi Z, Ma S, Ming J, Dong F, et al.
Cell Death Dis
. 2022 Sep;
13(9):800.
PMID: 36123344
Long noncoding RNAs (lncRNAs) play crucial regulatory roles in the progression of various cancers. However, the functional roles of lncRNAs in breast cancer remain unclear. In this study, we investigated...
8.
He L, Feng A, Guo H, Huang H, Deng Q, Zhao E, et al.
Gastric Cancer
. 2022 Jan;
25(3):527-541.
PMID: 35094168
Background: Increasing evidence indicates that leucine-rich-alpha-2-glycoprotein 1 (LRG1) is associated with multiple malignancies, but whether it participates in gastric cancer (GC) angiogenesis remains unclear. Methods: The expression levels of LRG1...
9.
Larsen B, Kannan M, Langer L, Leibowitz B, BenTaieb A, Cancino A, et al.
Cell Rep
. 2021 Jul;
36(4):109429.
PMID: 34320344
Patient-derived tumor organoids (TOs) are emerging as high-fidelity models to study cancer biology and develop novel precision medicine therapeutics. However, utilizing TOs for systems-biology-based approaches has been limited by a...
10.
Purohit V, Wang L, Yang H, Li J, Ney G, Gumkowski E, et al.
Genes Dev
. 2021 Jan;
35(3-4):218-233.
PMID: 33446568
Pancreatic ductal adenocarcinoma is a lethal disease characterized by late diagnosis, propensity for early metastasis and resistance to chemotherapy. Little is known about the mechanisms that drive innate therapeutic resistance...